Search

Improved survival for adult Acute Lymphoblastic Leukemia (ALL) patients

Historical survival for patients 18-45 years with ALL is approximately 40 %. However the event free survival for ALL patients 18-45 years has improved to 73% following implementation of the NOPHO ALL2008 protocol in July 2008.

Read more

How can I start contributing?

Getting started is easy! Here are a few good-to-know tips, that will help you navigate the different aspects of the EHA Hub.

Read more

Press release: Theme of the Year and Patient Advocacy - 18th Congress of EHA - European Hematology Association

This year for the first time, the EHA congress program is complemented by a dedicated advocacy track. This track combines all patient and policy related sessions into one comprehensive full-day program on Saturday.

Read more

ABT-199: Novel Bcl-2 specific inhibitor updated results confirm substantial activity and durable responses in high-risk CLL.

Chronic Lymphocytic Leukaemia (CLL) is the most common leukemia in adults in the Western world and is diagnosed in approximately 5 persons per 100,000 population per year.

Read more

Publications

Matching-adjusted indirect comparison of asciminib versus other treatments in chronic-phase chronic myeloid leukemia after failure of two prior tyrosine kinase inhibitors
Atallah E, Mauro MJ, Hochhaus A, Boquimpani C, Minami Y, Maheshwari VK, Saini L, Corbin R, Réa D.

Read more